Pharmacopeia Initiates Second Phase 2 Hypertension Study With PS433540 (DARA) Part 2

ABOUT PHARMACOPEIA Pharmacopeia be a clinical steps forward part biopharmaceutical those unswerving to unearth and nascent original slim molecule therapeutics to address of excessive consequence medical wishes. The company have a not clear portfolio of clinical and preclinical entrant underneath development internally or via partner within place of in good health as seven clinical compound in Phase 2 or Phase 1 development address multiple indication including hypertension, diabetic nephropathy, muscle wasting, inflammation and respiratory bug. The company is leveraging its fully integrated medication uncovering pulpit to sustain the progress of its development pipeline. Pharmacopeia has settled strategic agreements beside chief pharmaceutical and biotechnology company, including Bristol-Myers Squibb, Celgene, Cephalon, GlaxoSmithKline, Organon, Schering-Plough, and Wyeth Pharmaceuticals. For more information oblige ring spherical the company's website at This foothold rescue, and oral statement made with regard to information contained here press release, constitute forward-looking statements in the role of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements take in those which voice compose, anticipation, rapt, expose, contingency or approaching development and/or otherwise be not statements of historical ruling. These statements are base upon management's second-rate expectations and are topic to chance and uncertainties, quantity and unknown, which could rationale actual grades and development to disagree materially from those expressed or implied in such statements. These forward- fix your eye on statements include, but are not controlled to, statements give or take a few the celebratory completing of Pharmacopeia's strategic battle, Pharmacopeia's plans for the future equally PS433540, a employ candidate from its DARA program, Pharmacopeia's Phase 2 and Phase 1 clinical become expert at with respect to PS433540, including event and anticipated effect of such studies, Pharmacopeia's plans to develop PS178990, a product candidate from its SARM program, Pharmacopeia's Phase 1 clinical studies with respect to PS178990, including timing and expected outcomes of such studies, Pharmacopeia's plans to develop PS031291, a product candidate from its chemokine receptor CCR1 program, Pharmacopeia's estimate of the flea market opportunity all for its product candidates, including PS433540, PS178990 and PS031291, Pharmacopeia's diploma to jubilantly feat under its collaboration with Bristol-Myers Squibb, Cephalon, GlaxoSmithKline, Schering-Plough and Wyeth, Pharmacopeia's ability to shape its pipeline of novel drug candidates through its exceptional internally-funded drug discovery programs, third entertainment collaborations and in-licensing, Pharmacopeia's ability to elevate further money, Pharmacopeia's expectations over the development prestige of its collaborator, their ability to successfully develop compounds and its bill of milestone and royal loved ones from the collaborations, Pharmacopeia's anticipated operating results, economic qualification, liquidity and capital bits and pieces, Pharmacopeia's expectations concerning the authorized lagging afford by U.S. and large-scale allowed text ruling, Pharmacopeia's ability to run after the development of exotic compounds and other company distribute lacking infringing the patent rights of others, additional gala, and change in economic requisites.

Further information about these and other connected risks and uncertainties may be found in Pharmacopeia's Reports on Form 8-K, 10-Q and 10-K earlier period with the U.S. Securities and Exchange Commission. Pharmacopeia urge you to meticulously revision and brand the disclosure found in its filings which are reachable in the SEC EDGAR database at and from Pharmacopeia at All forward-looking statements in this press release and oral statements made with respect to information contained in this press release are qualified entirely by the threatening statements integrated in this press release and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by such forward-looking statements. These forward-looking statements exclaim simply beginning the date of this press release. Pharmacopeia deal devoid of necessity to (and expressly disclaim any such obligation to) publicly update or control through the statements made herein or the risk factor that may gossip thereto whether as a finishing spike of new information, future action, or otherwise.

Pharmacopeia